

Breast Cancer, Reconstruction, and Lymphedema:

The Role of the Symani® Surgical System in Comprehensive Cancer Care

Breast Cancer: The World's Most Prevalent Cancer



7.5 million women diagnosed with breast cancer in the past 5 years¹




1 in 8 women will develop breast cancer in their lifetime²



350k new cases per year in US³

Breast Reconstruction Options: Implant & Autologous

1.15 million mastectomies performed annually⁴



20% Autologous
Autologous reconstruction remains underutilized, despite the proven benefits^{5,6}



Natural look and feel using patients' own tissue



Long-lasting results without need for replacements



Lower risk, fewer complications, and reduced rejection rates

Lymphedema: A Common Post-Treatment Complication

Chronic extremity swelling and pain with limited surgical treatment options⁷



Affects **1 in 3** breast cancer survivors⁸



Fewer than **5,000** surgeries performed annually in the US⁹



Only **600** surgeons worldwide skilled in supermicrosurgery for lymphatic repair¹⁰

Symani
SURGICAL SYSTEM

This opens up everything.

Robotic-Assisted Microsurgery: Lead the Way to Better Patient Outcomes for Breast Reconstruction



Expand post-mastectomy care options

Address a full range of patient needs, including lymphedema prevention or treatment



Pioneer technology-enabled autologous reconstruction

Improve functional outcomes and lessen the risk for surgical complications



Enhance precision for optimal outcomes

Assist patients in achieving their goals of improved self-image and confidence, and restored quality of life

Enhancing Precision and Outcomes

High free flap survival rate¹¹

100%

breast site survival at 30-days

Reduced vessel trauma¹²

13% | **31%**

lower in veins | lower in arteries

Lower risk for occlusive thrombus¹³

0% | **6%**

with Symani vs manual

Fewer lymphedema symptoms¹⁴

86%

of arms showed volume reduction

References

- World Health Organization Breast Cancer Fact Sheet.
- American Cancer Society
- <https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html>
- Breast Reconstruction Market Global Forecast to 2026. Markets and Markets
- Clarivate Breast Implants and Reconstructive Devices Market Insights Report (533.30 implants, 137.40 autologous in 2023).
- Broyles, J. M., Balk, E. M., Adam, G. P., Cao, W., Bhuma, M. R., Mehta, S., Dominici, L. S., Pusic, A. L., & Saldanha, I. J. (2022). Implant-based versus Autologous Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis. Plastic and reconstructive surgery, Global open, 10(3), e4180.
- Schulze, H., Nacke, M., Gutenbrunner, C., & Hadamitzky, C. (2018). Worldwide assessment of healthcare personnel dealing with lymphoedema. Health economics review, 8(1), 10. <https://doi.org/10.1186/s13561-018-0194-6>
- Zou, L., Liu, Fh., Shen, Pp., et al. The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study. Breast Cancer 25, 309–314 (2018).
- Visconti G, Constantinescu T, Chen PY, et al. The Venous Lymph Node Flap: Concepts, Experimental Evidence, and Potential Clinical Implications. J Reconstr Microsurg. 2016;32(8):625–631. doi:10.1055/s-0036-1584527
- Badash, I., Gould, D. J., & Patel, K. M. (2018). Supermicrosurgery: History, Applications, Training and the Future. Frontiers in surgery, 5, 23. <https://doi.org/10.3389/fsurg.2018.00023>
- PRIMO PMCF clinical study. Data on file as of June 2023.
- Ballestin A, et al. Microsurgical robotic system enables the performance of microvascular anastomoses: a randomized in vivo preclinical trial. Sci Rep. 2023;13(1):14003. doi: 10.1038/s41598-023-41143-z. Data derived from animal models may not be predictive of human clinical experience. Score includes vessel reaction, inflammation, host reaction. Total average host reaction score compared to manual.
- SAFE Microsurgery GLP preclinical study. Data on file.
- Lindenblatt N, et al. 100 anastomoses: a two-year single-center experience with robotic-assisted micro- and supermicrosurgery for lymphatic reconstruction. J Robot Surg. 2024;18(1):164. Published 2024 Apr 6. doi:10.1007/s11701-024-01937-3

Visit mmimicro.com for more information



The Symani Surgical System is authorized for use in the U.S. by the FDA and is a CE marked medical device. Caution: Federal law restricts this device to sale by or on the order of a physician. ©2024 Medical Microinstruments, Inc. All rights reserved.

5022 Gate Parkway
Building 500
Jacksonville, FL 32256

MKT-00050 Rev.00